Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 27, 2017
Aviva Ventures, Aviva plc’s venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage. The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide.